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ABSTRACT
Background: Granulosa cell  tumours
account for less than 5% of all  ovarian
malignancies. Limited data is available from
India.
Methods: 27 patients with diagnosis of
granulosa cell  tumour of the ovary were
treated between 1991 and 2003 at our
Institute. The surgical records were
reviewed and the patients were staged
according to the FIGO system. The clinical
and histological findings are correlated with
prognosis and survival.
Results: Mean age at diagnosis was 46.2 (2-
64) years. The number of patients in various
stages was I-19; I I -1; I I I -5 and IV-2.
Menstrual irregularity was diagnosed in
22%, and postmenopausal bleeding in 7.4%
of women. Twenty-five patients were
treated with primary surgery, 9 patients
received adjuvant chemotherapy (CT) and
only one patients received chemotherapy as
primary treatment.  Overall  survival was
82% at 5 years.  Overall survival for stage
I was 100% after 5 and 10 years  and in
stage II-IV, was 56.4% after 5 and 10 years.
Mean tumour size was 18cm (range 3-30
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cm). Women with larger tumour diameter
(>15cm) had significantly worse outcome
than those with tumours of smaller
diameter (P<0.05).  The frequency of
observed mitosis influenced the survival
rate; with 0-3/10 HPF the survival was
100% in 5 years and with 4/10 HPF the
survival was 2.6 years.
Conclusion: The tumour size, mitotic rate
and stage of disease are well-defined
variables and influence the survival
significantly and should be considered as
important prognostic factors for treatment
planning.
INTRODUCTION
Granulosa cel l  tumours comprise 5% of al l
mal ignant ovarian tumours and account for
approximately 70% of mal ignant sex cord-
stromal tumours.1 Granulosa cell tumours have
been diagnosed from infancy through the tenth
decade of l i fe,  the peak incidence being
perimenopausal decade. The mal ignant
potent ial  of  these tumours is low and
recurrences, are often late and found in 10-33%.2
A variety of microscopic patterns have been
described and di fferent patterns can occur
within the same tumour.3 Many investigators
have found that age, stage, mitotic index and size
of tumour to be of prognostic importance.  In
poor risk patients the risk for metastases even
after long delay, is substantial.4
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We reviewed the care records of 27
patients diagnosed to have granulosa cel l
tumours at AIIMS from 1991 through 2003. The
clinical and histological findings were correlated
with prognosis and survival.
MATERIALS AND METHODS
During the 13 year period 1991-2003, 27 women
with histological ly veri f ied granulosa cel ls
tumour were treated at the Gynaecologic
Tumour Cl inic.  Al l   pat ients were staged
according to FIGO. The patients were divided
into subgroups according to age, stage, mitotic
rate, tumour size and histological features.  The
individual and mean mitot ic rates were
calculated in the subgroup.  Surgical treatment
varied from total  abdominal hysterectomy,
bilateral salpingo-oophorectomy and infracolic
omentectomy to unilateral ovariotomy(Table-1).
Adjuvant chemotherapy was given to 2 patients
using melphalan as a single agent therapy, and
f ive pat ients received combinat ion of
cyclophosphomide and cisplatin (CP) therapy.
One pat ient received combinat ion of
carboplatinum and cyclophosphomide (CE)  and
in one patients 2 cycles of CP and 4 cycles of CE
combination was used as an adjuvant treatment.
Only in one patient  bleomycin, etoposide and
cisplatin combination therapy was used as a
primary treatment (Table -2).
The data has been censored on 31st
December 2003, of the 27 patients 24 patients
were evaluable for treatment and response as
three pat ients after ini t ia l  v is i t  received
treatment elsewhere. Statistical analysis was
performed using the statistical package stata 8.0
(inter coiled version).  Kaplan –Meier estimates
of survival probabilities were calculated.
RESULTS
The age of patients at the time of diagnosis
ranged from 2 to 64 years with a mean of 46.8
years. Twelve women (44%) were postmen-
opausal at the time of diagnosis.  Eleven patients
(40%) were less than 40 years and one patient
was in premenarchal age group. The
symptomatology was similar in most cases and
often related to hormonal act iv i ty.  Most
commonly the patients consulted a gynaecologist
because of menstrual disturbances (29.6%) or
bleeding postmenopausally (7.4%).  Secondary
amenorrhoea was a presenting symptom in two
(7.4%) pat ients.  Six pat ients (22.6%) had
noticed a distended abdomen or painful
resistance in the abdomen.  Only four (14.8%)
had symptoms from urinary tract (Table-1.)
Endometrial tissue was obtained shortly
before or at the ini t ia l  laparatomy from 19
patients.  Simple hyperplasia was diagnosed in
31% of them, proliferative endometrium in 42%,
secretory endometrium in 17% and atypia of
endometrial cells in 10% of the cases. Surgical
treatment was employed in all cases except two.
Ten patients (37%) had unilateral salpingo-
oophorectomy with or with out omentectomy.
Fourteen pat ients (52%) underwent total
abdominal hysterectomy and bilateral salpingo-
oophorectomy.   One patient underwent primary
debulking surgery and one patients underwent
secondary  debulking surgery fol lowing
chemotherapy. (Table –1)
Nineteen patients were in clinical stage I
and only one had stage II  disease.  Seven
patients had disease outside the pelvic region;
5 were in stage I I I  and 2 were in stage IV
(Table-1). In 13 patients the histological pattern
was diffuse, 10 patients had trabecular pattern
and in 4 patients there was a microfollicular
pattern. Eighteen pat ients  (66.6%)  had a
tumour size ≤ 15 cm in diameter and 9 ( 33.3%)
patients had tumour size > 15 cm in diameter.
Mean tumour size was 10.5 cm (4-25cm),
survival according to tumour size is shown in
Fig. 1.  Survival curves for patients with clinical
stage I and II-IV disease are given in Fig. 2 the
relative survival being significantly better in the
former, P<0.001.
The mitot ic rate was evaluated in 21
patients, in 8 ( 38% ) patients the frequency was
<4 mitosis / 10 HPF, in 13 ( 62% )  patients it
was ≥4 mitoses / 10 HPF.  The overall mean
mitotic rate per 10 HPF was 5.8 mitoses (range
0-15).  The survival in patients with mitotic rate
of  <4 / 10HPF was 100% at 5 years. With the
increase in mitotic rate the survival decreases,
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Table:1. Patients Characteristics
Characteristics No. of patients Percentage
(n=27)
Age (Years)
 <20 1 3.7
 21-30 3 11.1
 31-40 7 25.9
 41-50 12 44.4
 51-60 2 7.4
 61-70 2 7.4
Presenting symptoms
Irregular Vaginal bleeding 8 29.6
Menorrhagia 4 14.8
Amenorrhoea 2 7.4
Post menopausal bleeding 2 7.4
Precocious puberty 1 3.7
Abdominal pain/ distension/ mass 6 22.6
Urinary Symptoms 4 14.8
Surgery performed
Unilateral saplingo Ovariotomy 9 33.3
LSO + Rt ovarian cystectomy 1 3.7
TAH + USO 3 11.2
TAH + BSO 6 22.5
TAH + BSO + omentectomy 5 18.5
Primary debulking 1 3.7
Secondary debulking 1 3.7
None 1 3.7
Stage of disease
I 19 70.4
I I 1 3.7
I I I 5 18.5
I V 2 7.4
TAH – Total abdominal hysterectomy, USO – Unilateral salpingo – oophorectomy,
BSO – Bilateral salpingo – oophorectomy, LSO – Left salpingo – oophorectomy.
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Table: 2 Chemotherapy for Granulosa cell tumours
S. Disease status of patients CT regimen No. Of Current status of patient
No. cycles
1 S1  - HMA # Melphalan 9 NED/9.4 Years
2 S3  - no RD* Melphalan 9 NED/4 Years
3 S1  - HMA CE++ 6 NED/4 Years
4 S2  - CP** 6 NED/8 Years
5 S3  - Minimal RD CP+CE 2+4 NED/8 Months
6 S3  - no RD CP 6 NED/1.5 Years
7 S3  - Gross RD CP 6 alive with residual disease
8 S3  - Gross RD CP 2 Died of progressive disease
9 S4  -  Pleural effusion+/Liver CP 3 Died of progressive disease
metastasis
10 S4  -    Lung metastasis BEP*** 4 Died due to post op
complications
# - High mitot ic act ivi ty  * -  Residual disease, + - Pleural effusion  ** - Cyclophosphomide & cisplat inum  *** -
Bleomycin, etoposide & cisplat inum ++ carboplat inum, & cyclophosphomide
NED : No evidence of disease.  S1 – Stage 1, S2 – Stage 2, S3 – Stage 3.
MI: Mitotic Index
Fig. 3. Survival curves according to mitotic rate in 21 of
27 patients with granulosa cell tumour of the ovary.
the median survival  for pat ients with the
mitotic rate of ≥4 / 10 HPF is about at 2 years
(Fig. 3).
The recurrence rate was 11%, all patients
who presented with recurrent disease had
abdomino-pelvic metastases.  The mean time
from initial diagnosis to recurrence was 3 years
and the mean tumour size in these patients was
16 cm and the mean mitotic rate was 8/10 HPF
(Table-3). At the end of the study 12 patients are
alive with no evidence of disease, 1 patients is
alive with disease, 3 patients died of progressive
disease, one died of postoperative complications
and one died due to unrelated cause.  Nine
patients were lost to follow up (Table -4).
DISCUSSION
From this study and other previous reports it
appears that granulosa cell tumours of the ovary
is an uncommon gynaecological malignancy
with a peak incidence in the f i rst  post
menopausal decade. In our series an increased
incidence is noted in the age group 41 to 50 years
with a mean age of occurrence at 46.8 years,
which is younger than those in several other
reports.5
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The main purpose of this study was to
evaluate possible prognostic factors such as
stage, size of tumour and frequency of mitosis
on the survival rate.  Age at diagnosis was not
found to influence tumour mortality, whereas in
other studies the prognosis was better for women
under 40 years of age.6,7 Majority of patients
were diagnosed in stage I opposed to epithelial
ovarian carcinoma which is usually diagnosed in
stage III.  This is due to the hormonal activity
of these tumours causing bleeding disturbances
as present ing symptoms paral lel  to the
symptomatology in endometrial carcinoma.8-10
Factors shown in our study to be
associated with better prognosis are consented
mainly with the stage of disease, tumour size
and mitotic activity of the tumour. There are
some reports that tumour size is of prognostic
value.6,11 In the present series relative survival
tend to be significantly better for women having
small  tumours compared with those having
larger ones (Fig -1).
Fig 1. Survival curves according to tumor size in 24 of
27 patients with granulosa cell tumours of the
ovary.
Note: T. S: Tumor size
The 5 year survival of our granulosa cell
tumour patients was 100% when they were
diagnosed at stage I, but this figure dropped to
56.4% for stages III and IV(Fig. 2).  Other studies
have also stressed on the major importance of
the stage of disease on survival.6,7,12 Histological
appearance of tumour and i ts relat ion to
prognosis has been discussed by various
authors. Kottmeir29 thought that a sarcomatoid
pattern implied a worse prognosis but others do
not agree.14,15 In our study no signif icant
correlation could be established between the
histological type of tumour and survival. Of the
different histological subtypes, the diffuse and
the trabecular subtype seemed to be more
aggressive on the basis of the higher mitotic rate
observed in these tumours. Norris and Taylor16
did not find any relation between the degree of
atypia, mitotic activity, and prognosis, while
others found that grading for mitotic activity is
of some value, especially when the tumour had
not spread beyond the ovary.17,18 A posit ive
relationship between atypia and mitotic index
and recurrence rate has been reported.13 In our
study we found that four or more mitosis per 10
HPF indicated a higher risk and the mortality
increased with the mitotic index (Fig 3).
Fig.2 : Survival curves according to clinical staging in 24
of 27 patients with granulosa  cell tumor of the
ovary
A special feature of granulosa cell tumours
is the appearance of recurrences long after
treatment of the primary tumour, mean time for
recurrence after diagnosis was 5.6 years.6
Recurrences after more than 10 years are
reported by several authors.16,17,19 In our series
the mean time unti l recurrence was 3 years
(rage 1.5-9.4 years). All recurrences occurred in
both  pelvis and abdomen (Table 3).
The treatment of granulosa cell tumour
patients is not well established.  Some authors
have reported improved outcome in patients
treated with adjuvant radiation therapy, other
investigators have found no clear value in the use
of adjuvant radiat ion therapy. 20-22 Alkylat ing
agent chemotherapy has been used in patients
with granulosa cel l  tumours with responses
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Table: 3. Recurrences
Age In i t ia l M I * Pr imary Time Recurrent Site Treatment Outcome
S. No. Rx unt i l Given (months)
replace
(month)
35 I H * * USO 28 Abdomen+Pelvis Surgery alive
23 I M** * USO 48 Abdomen+Pelvis Surgery NED+
+CP (6) 16mon
32 I H BSO 32 Abdomen + Pelvis Surgery DOD++
+CP (2)
Note: * - Mitotic Index , ** - High MI, *** -  Moderate MI
Ned  No evidence of disease, Nod died of progressive disease
Table:4. Follow up of Patients with Granulosa Cell Tumours
Patient status Follow – up – period (years) Total (n = 24)
< 2 2 - 5 6 – 10
Alive and well 2 5 6 13
Alive with disease 1 - - 1
Died due to disease 3 - - 3
Died due to post op 1 - - 1
Complications
Died due to - 1 - 1
unrelated cause
Lost to follow – up 2 3 - 5
* - Residual disease
noted in various reports.23,24 Doxorubicin plus
bleomycin as wel l  as combinat ion of
dact inomycin, cyclophosphomide and 5-
fluorouracil have yielded at least two complete
responses.15,26 The most promising report of a
platinum based regimen included 9 responders
to the combination of cisplatinum, vinblastine
and bleomycin, in 11 previously untreated
patients with advanced disease.27 In our series
6 pat ients received combinat ion of
cyclophosphomide and cisplat inum as an
adjuvant chemotherapy. Of them 3 showed
complete response and one patient had partial
response with a median follow up of 2.7 years
(Table –5).  We found that patients with gross
residual disease at the time of initial surgery
were relat ively poor responders than the
patients with ei ther minimal or no residual
disease.
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Recently, Gynaecologic Oncology Group
have reported the largest series of women with
ovarian sex cord stromal tumours treated with
chemotherapy.  They used four cycles of
cisplatinum, bleomycin and etoposide.28 This
chemotherapy combinat ion was considered
active with 11 of 16 primary disease patients
and 21 of 41 recurrent disease pat ients
remaining progression free at a median follow
up of 3 years.  In our study only one patient with
stage IV disease had been treated with BEP
regimen, showed partial response but she died
due to postoperative complications following
interval debulking surgery.
In summary, granulosa cell tumours must
be regarded as ovarian tumours with a malignant
potential that is only slightly less than that of
the more common ovarian carcinomas.  Early
stage tumours with strong adverse prognostic
factors should be treated with adjuvant
chemotherapy.  In selecting patient for adjuvant
treatment one should take into account not only
tumour stage but also tumour size and mitotic
rate.  An accurate surgical staging is also
important in the treatment planning of these
tumours.  Recurrence is common and can occur
late. Treatment of recurrences with combination
chemotherapy is worth while.  In these cases of
stage I I I  and IV disease treatment is
individual ized, but consists mainly of
chemotherapy.
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